Medicare will cover weight-loss drugs under a deal between the Trump administration and drugmakers Eli Lilly and Novo Nordisk to cut prices for blockbuster diabetes and anti-obesity drugs.
Why it matters: About 10% of Medicare enrollees will be newly eligible for coverage of GLP-1 drugs because of the deal, a senior administration official told reporters Thursday.